Spots Global Cancer Trial Database for enfortumab vedotin
Every month we try and update this database with for enfortumab vedotin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer | NCT04223856 | Urothelial Canc... | Enfortumab vedo... Pembrolizumab Cisplatin Carboplatin Gemcitabine | 18 Years - | Astellas Pharma Inc | |
| Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer | NCT06394570 | Bladder Cancer | Enfortumab vedo... | 18 Years - | University of Texas Southwestern Medical Center | |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | NCT03869190 | Urothelial Carc... Bladder Cancer | Atezolizumab Enfortumab Vedo... Niraparib Magrolimab (Hu5... Tiragolumab Sacituzumab Gov... Tocilizumab Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | NCT03474107 | Ureteral Cancer Urothelial Canc... Bladder Cancer | Enfortumab Vedo... Docetaxel Vinflunine Paclitaxel | 18 Years - | Astellas Pharma Inc | |
| Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer | NCT04878029 | Infiltrating Bl... Locally Advance... Metastatic Urot... Unresectable Ur... | Cabozantinib S-... Enfortumab Vedo... Quality-of-Life... Questionnaire A... | 18 Years - | Emory University | |
| Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | NCT05756569 | Bladder Squamou... Locally Advance... Malignant Renal... Malignant Urete... Malignant Ureth... Metastatic Blad... Stage III Bladd... Stage IV Bladde... Unresectable Bl... Urachal Adenoca... Bladder Adenoca... | Biospecimen Col... Computed Tomogr... Enfortumab Vedo... Magnetic Resona... Pembrolizumab Questionnaire A... | 18 Years - | Emory University | |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | NCT04963153 | Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... | Biospecimen Col... Computed Tomogr... Enfortumab Vedo... Erdafitinib | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05014139 | Urinary Bladder... Carcinoma in Si... Carcinoma Trans... Non-muscle Inva... NMIBC | Enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer | NCT05775471 | Renal Pelvis an... | Biopsy Biospecimen Col... Enfortumab Vedo... MR Urography Nephroureterect... Pembrolizumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Renal Retention in High Grade Upper Tract Urothelial Cancer | NCT05656235 | High Grade Urot... Bladder Cancer Urothelial Carc... | Enfortumab vedo... Pembrolizumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma | NCT05923190 | Urothelial Carc... Metastatic Urot... Locally Advance... | Enfortumab vedo... Pembrolizumab | 18 Years - | Fox Chase Cancer Center | |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | NCT03869190 | Urothelial Carc... Bladder Cancer | Atezolizumab Enfortumab Vedo... Niraparib Magrolimab (Hu5... Tiragolumab Sacituzumab Gov... Tocilizumab Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Renal Retention in High Grade Upper Tract Urothelial Cancer | NCT05656235 | High Grade Urot... Bladder Cancer Urothelial Carc... | Enfortumab vedo... Pembrolizumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | NCT03288545 | Carcinoma, Tran... Urinary Bladder... Urologic Neopla... Renal Pelvis Ne... Urothelial Canc... Ureteral Neopla... Urethral Neopla... | enfortumab vedo... pembrolizumab cisplatin carboplatin gemcitabine | 18 Years - | Astellas Pharma Inc | |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05014139 | Urinary Bladder... Carcinoma in Si... Carcinoma Trans... Non-muscle Inva... NMIBC | Enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT04754191 | Metastatic Cast... | Enfortumab vedo... | 18 Years - | University of Utah | |
| A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) | NCT05524545 | Bladder Cancer Urothelial Carc... | Evorpacept Enfortumab Vedo... | 18 Years - | ALX Oncology Inc. | |
| A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection | NCT06011954 | Urothelial Canc... | Enfortumab Vedo... | - | Astellas Pharma Inc | |
| Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma | NCT05923190 | Urothelial Carc... Metastatic Urot... Locally Advance... | Enfortumab vedo... Pembrolizumab | 18 Years - | Fox Chase Cancer Center | |
| Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma | NCT06302569 | Bellini Carcino... Collecting Duct... Renal Medullary... | Pembrolizumab +... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | NCT02091999 | Metastatic Urot... | enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis | NCT06104618 | Metastatic Peni... Stage III Penil... Stage IV Penile... Unresectable Pe... | Enfortumab Vedo... | 18 Years - | Mayo Clinic | |
| Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) | NCT05915351 | Pancreatic Duct... Pancreas Adenoc... Pancreas Cancer | Enfortumab vedo... | 18 Years - | University of Kansas Medical Center | |
| A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | NCT04225117 | Locally Advance... | enfortumab vedo... pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract | NCT05868265 | Urothelial Carc... | Enfortumab Vedo... Radical surgery | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | NCT05756569 | Bladder Squamou... Locally Advance... Malignant Renal... Malignant Urete... Malignant Ureth... Metastatic Blad... Stage III Bladd... Stage IV Bladde... Unresectable Bl... Urachal Adenoca... Bladder Adenoca... | Biospecimen Col... Computed Tomogr... Enfortumab Vedo... Magnetic Resona... Pembrolizumab Questionnaire A... | 18 Years - | Emory University | |
| Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT04754191 | Metastatic Cast... | Enfortumab vedo... | 18 Years - | University of Utah | |
| Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin | NCT04960709 | Muscle Invasive... | Durvalumab Tremelimumab Enfortumab Vedo... Radical Cystect... | 18 Years - 130 Years | AstraZeneca | |
| Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer | NCT04878029 | Infiltrating Bl... Locally Advance... Metastatic Urot... Unresectable Ur... | Cabozantinib S-... Enfortumab Vedo... Quality-of-Life... Questionnaire A... | 18 Years - | Emory University | |
| Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma | NCT06302569 | Bellini Carcino... Collecting Duct... Renal Medullary... | Pembrolizumab +... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | NCT02091999 | Metastatic Urot... | enfortumab vedo... | 18 Years - | Astellas Pharma Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
